Elevated Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Elevated Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.12K	Hold	5	–	–	﹤0.01%	616
2026 Q1	$3.86K	Hold	5	–	–	﹤0.01%	577
2025 Q4	$3.86K	Buy	+5	New	+$3.4K	﹤0.01%	547
2021 Q1	$987K	Buy	1,956 +249	+15%	+$121K	0.38%	88
2020 Q4	$825K	Buy	1,707 +248	+17%	+$134K	0.36%	93
2020 Q3	$816K	Sell	1,459 -203	-12%	-$123K	0.38%	97
2020 Q2	$1.01M	Buy	+1,662	New	+$943K	0.48%	73

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Elevated Capital Advisors's REGN Position: Q2 2026 in Review

Elevated Capital Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 5 shares worth $3.12K. The position accounts for ﹤0.01% of the portfolio, ranked #616.

Elevated Capital Advisors first reported a position in REGN in Q2 2020 and has held it in 7 quarters since. The position peaked at $1.01M in Q2 2020. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Elevated Capital Advisors held 5 shares of Regeneron Pharmaceuticals worth $3.12K as of Q2 2026.
Elevated Capital Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Elevated Capital Advisors's portfolio in Q2 2026, its #616 holding.
Elevated Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 7 quarters since.
Elevated Capital Advisors's Regeneron Pharmaceuticals position peaked at $1.01M in Q2 2020.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.